Target intelligence / Profile preview

microRNA 8069 (MIR8069)

Target
MIR8069
Molecular classification
Other (microRNA, non-coding RNA)
01

Overview

MicroRNA 8069 is a member of the microRNA (miRNA) family of small non-coding RNAs, which function in post-transcriptional regulation of gene expression mainly by binding to complementary sequences in target messenger RNAs, leading to translational repression or degradation[6][4][3]. MIR8069 itself is rarely mentioned in the literature, and there is no well-documented biological pathway, established target protein, or validated gene regulatory network attributed to it. It is not currently recognized as a therapeutic target or druggable asset.\n\nRecent studies suggest that the ratio of miR-3940-5p to miR-8069 in urine exosomes can serve as a novel diagnostic biomarker for pancreatic ductal adenocarcinoma, with specificity but limited sensitivity compared to existing markers. miR-8069 has also been found deregulated in a longitudinal Parkinson disease cohort, suggesting possible use as an early progression biomarker, but there is no mechanistic biology linking MIR8069 to disease pathways[1][5]. As with most miRNAs, its potential mechanistic functions would likely fall under gene expression regulation, but no target genes or direct functional roles are known for MIR8069 specifically. No drugs are reported to interact with or modulate MIR8069, nor is it used for patient selection or as a safety biomarker.\n\nLimitations:\n- The target appears to be poorly characterized and possibly only designated by its sequence.\n- Not listed in major miRNA functional or therapeutic databases; no PubMed entry dedicated to its function.\n- No structure, interacting molecules, or disease mechanism attributed to MIR8069.\n- Most information is contextual (within biomarker studies using panels of miRNAs) rather than mechanistic or therapeutic.\n\nIn summary, MIR8069 is best described as an uncharacterized microRNA investigated almost exclusively as a denominator in certain disease biomarker panels (notably in urine exosomes for pancreatic cancer) and lacks independent validation as a therapeutic target or regulator[1][5].

Other names
MIR8069MIR8069-2hsa-mir-8069-2microRNA 8069-2
02

Disease associations

Potential biomarker for pancreatic ductal adenocarcinomaPossible biomarker in Parkinson disease research
03

Biomarkers

Potentially the miR-3940-5p/miR-8069 ratio (urine exosome-based biomarker in pancreatic ductal adenocarcinoma) [1]possibly early marker in longitudinal Parkinson disease cohort [5]

Beyond the preview

Go deeper on microRNA 8069 (MIR8069).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on microRNA 8069 (MIR8069).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call